<?xml version="1.0" encoding="UTF-8"?>
<p id="p1175">The US CDC developed a tetravalent chimeric dengue vaccine by splicing the prM and E genes of attenuated DENV-1, -3, and -4 into NS RNA of the successfully attenuated DENV-2 16681 PDK-53. The tetravalent vaccine candidate has undergone preclinical testing in mice and nonhuman primates comparing intradermal and subcutaneous routes of delivery. The intradermal delivery of a tetravalent preparation of DENVax (10
 <sup>5</sup> Â pfu per DENV-type) produced superior immune responses in cynamolgous monkeys (
 <xref rid="bib245" ref-type="bibr">Osorio et al., 2011a</xref>, 
 <xref rid="bib246" ref-type="bibr">Osorio et al., 2011b</xref>).
</p>
